---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-012222"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T12:01:10.769466+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat

## Summary
- Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.
- Full-year 2023 net loss $50.6M ($0.51/share) vs net loss $22.3M ($0.26) in 2022.
- Operating cash flow $2.3M; cash and investments $87.0M at Dec 31, 2023.
- 2024 operating expense expected flat vs 2023; cash use expected to decline substantially in 2025.
- 10 new licenses signed in 2023, 6 new antibodies entered clinic; launched OmniDeep and Omni dAb platforms.

## SEC filing metadata
- accession: 0001628280-24-012222
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/oabi-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-012222
- JSON: https://secwatch.observer/filing/0001628280-24-012222.json
- Plain text: https://secwatch.observer/filing/0001628280-24-012222.txt

## Key facts
- Earnings Releases
  OmniAb, Inc. reported 12 months ended December 31, 2023 results: revenue $34.2 million, net income $50.6 million, EPS $0.51 per share.
  - Period: 12 months ended December 31, 2023
  - Revenue: $34.2 million
  - Net income: $50.6 million
  - EPS: $0.51 per share
  - Result: reported results
  source text: or $0.14 per diluted share, compared with net income of $6.8 million, or $0.07 per share, for the same period in 2022. Full Year 2023 Financial Results Revenue for 2023 was $34.2 million, compared with $59.1 million for 2022, with the decrease primarily due to the recognition of TECVAYLI ® milestones of $10.0 million in 2023 compared with $25.0 million in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm
- Earnings Releases
  OmniAb, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million, net income $14.1 million, EPS $0.14 per diluted share.
  - Period: three months ended December 31, 2023
  - Revenue: $4.8 million
  - Net income: $14.1 million
  - EPS: $0.14 per diluted share
  - Result: reported results
  source text: as we are now staffed and resourced to efficiently leverage the future growth of the business.” Fourth Quarter 2023 Financial Results Revenue for the fourth quarter of 2023 was $4.8 million, compared with $35.3 million for the same period in 2022, with the decrease primarily due to the recognition of a $25.0 million milestone payment in the prior-year period related
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000162828024012222/0001628280-24-012222-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.